Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BridgeBio Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was €-567.6 Mil. BridgeBio Pharma's average total tangible assets for the quarter that ended in Mar. 2026 was €968.8 Mil. Therefore, BridgeBio Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -58.59%.
The historical rank and industry rank for BridgeBio Pharma's Return-on-Tangible-Asset or its related term are showing as below:
FRA:2CL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -115.44 Med: -67.21 Max: -31.17
Current: -70.39
During the past 9 years, BridgeBio Pharma's highest Return-on-Tangible-Asset was -31.17%. The lowest was -115.44%. And the median was -67.21%.
FRA:2CL's Return-on-Tangible-Asset is ranked worse than 70.62% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs FRA:2CL: -70.39
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BridgeBio Pharma Return-on-Tangible-Asset Related Terms
BridgeBio Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs EXEL, IONS, JAZZ: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -58.59% mean?
BridgeBio Pharma (FRA:2CL) has a Return-on-Tangible-Asset of -58.59% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #1000 out of 1416 companies in the Biotechnology industry, placing it in the top 70.6%.
Is BridgeBio Pharma's Return-on-Tangible-Asset too high?
BridgeBio Pharma's current Return-on-Tangible-Asset is -58.59%. Based on the distribution chart, BridgeBio Pharma ranks #1000 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Return-on-Tangible-Asset compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #1000 out of 1416 companies for Return-on-Tangible-Asset. This places BridgeBio Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Return-on-Tangible-Asset is -58.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €126.79, compared to a current price of €76.60 — trading 39.6% below its estimated fair value. The current Return-on-Tangible-Asset is -58.59%. BridgeBio Pharma's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Return-on-Tangible-Asset is -58.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €76.60 is trading 39.6% below its estimated GF Value™ of €126.79.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Return-on-Tangible-Asset: -58.59%
GF Value™: €126.79 vs. price of €76.60 (39.6% below fair value)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
73GF Score
Get the complete analysis for FRA:2CL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
